> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** AI Drug Discovery **Published:** 2026-10-24 06:07 KST **Entry ID:** 135 **Tags:** #id135 #digest-2026-10-24 #loop-001-v1-1 #saturday-scan #recycled-top-ladder-fallback #first-novel-9p24.1-jak-blockade-lymphoma-dataset #first-novel-MIC13-cristae-dysfunction-multiomics-dataset #first-novel-vervet-age-related-muscle-decline-multiomic-dataset #9p24.1 #JAK1 #JAK2 #JAK-STAT --- ## 🔬 Today's Top Findings ### 1. [AI Drug Discovery + Dual-Axis Checkpoint Strategy + 9p24.1 Amplification + Ruxolitinib + Pembrolizumab Combination + First NOVEL 9p24.1 JAK-Blockade Lymphoma Dataset of the Day] GSE351196 'Targeting the 9p24.1 Axis with JAK Inhibition and Immune Checkpoint Blockade in Lymphomas' (Homo sapiens, score 6, n=21, raw TXT files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/22 = 2 days ago = FRESHEST NOVEL accession of the day, protein-design modality, query 'OpenFold weights') is the FIRST NOVEL 9p24.1 dual-axis checkpoint-blockade dataset to surface in the prior id:130-id:134 retention window ### 2. [Fibrosis Lane + Hepatic Lane + Mitochondrial Hepatopathy + MIC13 / MICOS Cristae Disruption + iPSC-Derived Hepatocytes + Early Fibrotic Remodelling + First NOVEL MIC13-Cristae-Dysfunction Multi-Omics Dataset of the Day] GSE313628 'MIC13-linked cristae disruption causes metabolic failure and early fibrotic remodelling in mitochondrial liver disease' (Homo sapiens, score 6, n=16, raw CSV files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/09/14, PMID 42744797, protein-design modality, query 'extracellular matrix multiomics') is the FIRST NOVEL MIC13-cristae-dysfunction multi-omics dataset to surface in the prior id:130-id:134 retention window ### 3. [Longevity Lane + Comparative Primate Aging + Vervet Monkey (Chlorocebus sabaeus) + Gait-Speed Stratification + Transcriptome + miRNome + Methylome + First NOVEL Vervet-Age-Related-Muscle-Decay Multi-Omic Dataset of the Day] GSE349369 'Integrative Multi-omics Analysis Reveals Molecular Signatures of Age-Related Decline in Vervet Skeletal Muscles' (Homo sapiens ### 4. Chlorocebus sabaeus, score 6, n=29, raw IDAT + XLSX files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/02, mixed modality, query 'frailty multi-omics') is the FIRST NOVEL vervet age-related muscle-decline multi-omic dataset to surface in the prior id:130-id:134 retention window ## 📋 Synthesis The 2026-10-24 06:00 KST research-watcher scan ran via `bash run.sh scan` per brown-biotech-cron-silent-failure-diagnostics section 20 fixed-instruction: 114 fresh hits across the standard 27-query coverage landed in research-watcher/output/2026-10-24/scan/ (scan.md + scan.json + hits.jsonl all present, 0 source errors). The score-9 top band is again 100% RECYCLED at accession level from the prior id:130-id:134 retention window (GSE349377 CRISPRi-biomaterial-adhesion, GSE328275 TNBC-CD45-scRNA, GSE328422 lymph-node-spatial, GSE326553 opioid-spatial, GSE346380 CosMx-LUAD, GSE348495 CosMx-CRC, GSE288340 Xenium-anti-BCMA-marrow, GSE311507 HNSCC-states, GSE281462-65 3D-chromatin-GWAS quartet) - 0 score-9 first-NOVEL harvest, matching the recycled-top-ladder situation of id:130 through id:134. Per the section 20 recycled-top-ladder-fallback pattern, the actionable NOVEL harvest today comes from a TRI-FILTER through accession-NOT-in-id:130-id:134-retention-window + bb-domain-keyword-positive (9p24.1 + JAK1/2 + PD-L1/PD-L2 + lymphoma + checkpoint blockade + ruxolitinib/pembrolizumab + MIC13 + cristae + mitochondrial hepatopathy + early fibrosis + iPSC-derived hepatocytes + vervet monkey + gait speed + frailty + miRNome/methylome) + pdat-recent + mammalian-taxon-preferred: 3 NOVEL signals across 3 distinct BB lanes (AI-DD / Clinical Lane, Fibrosis+Hepatic Lane, Longevity Lane). All 3 picks are accession-level NOVEL vs id:134 (yesterday's DYRK1A-CD47 surface-abundance + MASH-to-HCC hyperinflammatory atlas + Rec-ID photocatalytic proximity-labeling triad) - zero overlap, so the NOVELTY GATE is met at 3/3 rather than the required 2/2, and lane diversity is 3/3. Each accession was verified against its NCBI GEO esummary record (title, depositor abstract, taxon, pdat, sample count, supplementary-file listing) rather than title-matching alone; GSE351196 and GSE349369 carry no PMID in GEO yet, so their summaries were read directly from the depositor abstract. Runner-up for the Longevity lane is GSE351786 (inflammatory signature of subcutaneous fat after weight loss and regain in women undergoing repeated bariatric surgery, pdat 2026/10/22, score 8, n=38), which should be folded into the longevity service line's next pass. --- ## 🎯 Highlights ### 1. Signal 1 (AI Drug Discovery Lane + Clinical & Regulatory Lane + 9p24.1 Amplification + JAK1/2 Inhibition + Dual Checkpoint Strategy + Ruxolitinib + Pembrolizumab + First NOVEL 9p24.1 JAK-Blockade Lymphoma Dataset of the Day) - GSE351196 'Targeting the 9p24.1 Axis with JAK Inhibition and Immune Checkpoint Blockade in Lymphomas' (Homo sapiens, score 6, n=21, raw TXT files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/22 = 2 days ago = FRESHEST NOVEL accession of the day, protein-design modality, query 'OpenFold weights'). KEY mechanistic content, read from the depositor abstract: amplification of chromosome 9p24.1 drives COORDINATED upregulation of JAK-STAT signaling together with the immune checkpoint ligands PD-L1 and PD-L2, promoting lymphoma cell survival and immune evasion. PD-1 blockade shows substantial activity in 9p24.1-spectrum lymphomas but responses remain incomplete, particularly outside classical Hodgkin lymphoma. The authors hypothesized that DUAL TARGETING of the 9p24.1 axis via JAK1/2 inhibition could enhance checkpoint blockade by simultaneously disrupting tumor-intrinsic survival signaling AND reprogramming the tumor microenvironment. Using 9p24.1-amplified lymphoma cell lines, bulk RNA-seq, a 3D immune co-culture organoid platform, ex vivo patient PBMCs, syngeneic and humanized murine models, and spatial CosMx protein tissue microarray analysis, ruxolitinib was evaluated alone and in combination with pembrolizumab. Ruxolitinib preferentially reduced PD-L1/PD-L2 and c-MYC expression in 9p24.1-amplified lines and induced transcriptional upregulation of antigen-presentation pathways including MHC class II-associated genes. Combination therapy enhanced CD3+ T-cell tumor infiltration and increased tumor-cell apoptosis versus monotherapy, reduced Tregs and myeloid-derived suppressor cells while increasing CD4+/CD8+ activation markers, and in vivo suppressed tumor growth and prolonged survival. Why it matters for BB: this is a clean, decision-ready example of the compound-rescue logic that the Brown Biotech refractory-cancer lane sells - not 'block the checkpoint' (already standard) but 'find the upstream chromosomal amplifier that co-drives both the survival signaling and the checkpoint ligand, and interrupt it so monotherapy becomes combination-ready.' It also gives the Brown Biotech AI-DD target-inference stack a concrete, citable case where a genetic lesion (9p24.1 amplification) is the correct unit of inference rather than the gene or the ligand - exactly the reasoning-layer move that distinguishes Brown Biotech from a database lookup. The 3D immune co-culture organoid platform and the CosMx spatial TMA arm are both directly reusable experimental-design assets for the fibrosis and multi-omics service lines. Caveat for honesty: the dataset has no PMID in GEO yet and n=21 is a small mechanistic series - treat it as a high-value hypothesis-generating input requiring the standard QC notebook before ingestion, not an established clinical claim. ### 2. Signal 2 (Fibrosis Lane + Hepatic Lane + Mitochondrial Hepatopathy + MIC13 / MICOS Cristae Disruption + iPSC-Derived Hepatocytes + Early Fibrotic Remodelling + First NOVEL MIC13-Cristae-Dysfunction Multi-Omics Dataset of the Day) - GSE313628 'MIC13-linked cristae disruption causes metabolic failure and early fibrotic remodelling in mitochondrial liver disease' (Homo sapiens, score 6, n=16, raw CSV files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/09/14, PMID 42744797, protein-design modality, query 'extracellular matrix multiomics'). KEY mechanistic content, read from the depositor abstract and verified against the linked PubMed record: mitochondrial diseases are highly heterogeneous and nearly 20% of cases involve severe liver pathology; MIC13-mediated hepato-encephalopathy is a rare mitochondrial hepatopathy with profound liver involvement, yet the mechanism by which MIC13 deficiency causes severe hepatic dysfunction remains poorly understood. The authors report an additional individual carrying a pathogenic MIC13 variant (c.260-2A>G) with severe multisystem disease involving liver, brain and kidney. They generated an iPSC-BASED MODEL by introducing the disease-causing variant and differentiating the cells into INDUCED HEPATOCYTES (iHeps), which reproduced the cristae defects observed in patient samples. MIC13 is a non-ETC protein and a key component of the MICOS complex essential for cristae formation. Comprehensive multi-omics revealed extensive METABOLIC REWIRING: disrupted amino acid turnover, accumulation of TCA and urea-cycle intermediates, and profound alteration of ONE-CARBON METABOLISM affecting methylation potential, redox homeostasis and detoxification. Lipid metabolism was impaired with incomplete beta-oxidation, increased ketogenesis and diminished lipid storage. At the cellular level, extensive EXTRACELLULAR MATRIX REMODELLING and enhanced cell migration indicated an EARLY FIBROTIC PHENOTYPE. The paper provides the first mechanistic link between MIC13-dependent cristae disruption and hepatic metabolic failure. Why it matters for BB: this is the highest-value fibrosis-lane signal in days because it demonstrates the exact methodological move the Brown Biotech fibrosis service line has been promising clients and has not yet been able to show publicly - building a PATIENT-GENOTYPE-DERIVED HUMAN DISEASE MODEL and reading FIBROSIS AS AN EARLY, DOWNSTREAM PHENOTYPE rather than as the endpoint. Three concrete payoffs: (a) the iPSC-iHeps platform is a human, non-animal, genotype-first fibrosis assay that maps onto Brown Biotech's own anti-fibrotic service positioning and would be a strong anchor for a Paid Brief; (b) it reframes fibrosis as an EMERGENT property of organelle failure - cristae/ETC topology breaks, one-carbon and redox metabolism fail, and ECM remodelling follows - which gives the reasoning layer a mechanistic chain (membrane architecture -> metabolism -> matrix) rather than a list of differentially expressed genes; (c) it links a rare mitochondrial hepatopathy to a COMMON fibrosis axis (ECM remodelling, migration), which is how the lane can be sold to a general fibrosis client rather than only to a niche one. Design continuity: this composes with id:134's MASH-to-HCC hyperinflammatory atlas and id:133's AP-1 lung-ECM developmental-vs-fibrotic gate to form a three-day arc on fibrosis MECHANISM rather than fibrosis description. Caveat for honesty: n=16 and a single patient variant - the dataset is a mechanism paper, not a cohort. ### 3. Signal 3 (Longevity Lane + Comparative Primate Aging + Vervet Monkey (Chlorocebus sabaeus) + Gait-Speed Stratification + Transcriptome + miRNome + Methylome + First NOVEL Vervet-Age-Related-Muscle-Decay Multi-Omic Dataset of the Day) - GSE349369 'Integrative Multi-omics Analysis Reveals Molecular Signatures of Age-Related Decline in Vervet Skeletal Muscles' (Homo sapiens; Chlorocebus sabaeus, score 6, n=29, raw IDAT + XLSX files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/02, mixed modality, query 'frailty multi-omics'). KEY mechanistic content, read from the depositor abstract: age-related decline in skeletal muscle function, manifesting as SLOWER GAIT SPEED, contributes significantly to frailty and loss of independence. To uncover the molecular basis of this decline, the authors investigated COORDINATED CHANGES ACROSS THE TRANSCRIPTOME, miRNOME AND METHYLOME in vastus lateralis muscle from female vervet monkeys (Chlorocebus aethiops sabaeus) exhibiting normal versus declining gait speed. Why it matters for BB: this is a direct, citable upgrade to the Brown Biotech longevity lane and to the comparative-biology dossier, for four reasons. (a) It applies a FUNCTIONAL PHENOTYPE (gait speed) rather than chronological age to stratify a non-human primate cohort - this is exactly the stratification principle the Brown Biotech longevity line needs, because it sidesteps the age-vs-biomarker confounding that weakens most aging datasets. (b) The three-layer design (mRNA + miRNA + DNA methylation) is a rare, deliberately integrative design that gives the reasoning layer three independent evidence channels for one phenotype, which is what makes a 'longevity' claim decision-ready instead of speculative. (c) Vervet monkeys are a translational bridge between rodent aging models and human cohorts, so the dataset supports the comparative-biology dossier argument directly (design continuity with id:130's canine-beagle Dog Aging Project pair - this is the primate tier of the same comparative ladder). (d) The raw IDAT + XLSX payload means the methylation layer can be ingested without conversion friction, matching the Brown Biotech multi-omics QC template expectation. Caveat for honesty: n=29, female-only, one muscle, and the abstract does not yet name the specific signatures - treat it as an ingestion-priority reference dataset for the longevity service line, not yet as a mechanistic claim. ### 4. Cross-signal synthesis (the NEW observation of the day) - the three NOVEL signals are about INTERVENTION LAYER SELECTION, not about target discovery. Signal 1: do not block the checkpoint ligand, block the chromosomal amplifier that co-drives the ligand and the survival signaling (9p24.1 -> JAK-STAT + PD-L1/PD-L2), so monotherapy becomes combination-ready. Signal 2: do not chase downstream ECM genes, model the patient genotype in human hepatocytes and read fibrosis as an early consequence of cristae/mitochondrial failure (MIC13 -> cristae -> one-carbon/redox failure -> ECM remodelling). Signal 3: do not use chronological age to define the phenotype, use a functional readout (gait speed) to stratify a primate cohort and then read three molecular layers in register (transcriptome + miRNome + methylome). Read together they say: THE PRODUCTIVE INTERVENTION IS SELECTED AT THE LAYER WHERE THE LAYER AMPLIFIES (a chromosomal amplicon, an organelle-structure gene, a functional performance phenotype) rather than at the layer where the phenotype is measured. That is a single, teachable reasoning move, and it is precisely the Brown Biotech Paid Brief SoI proposition - the reasoning layer does not sell the reader 'lymphoma is a hot target' or 'muscle aging is a hot target' (database rows), it sells the observation that the decision-relevant unit is the amplifying layer, and it can name that layer with a citable dataset in each case. Brown Biotech implication: 'amplifying-layer intervention selection' is now the third consecutive digest-level thesis after node identity (id:133), checkpoint/surface state (id:134), and now intervention layer - a three-digest arc, which is the threshold at which the SoI reasoning layer should promote it from a per-brief move to a named published capability (a Brown Biotech 'Amplifying-Layer Intervention Selection' method note). The infrastructure lane gains a supporting asset today as well: GSE351196 ships a 3D immune co-culture organoid platform and a CosMx spatial TMA arm that can be reused as validation scaffolds for the AI-DD and fibrosis service lines. --- ## 💼 Next Steps - **[Open GSE351196 in GEO (9p24.1 JAK inhibition + immune checkpoint blockade in lymphomas, n=21)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE351196)** - **[Read 9p24.1 amplification + ruxolitinib/pembrolizumab lymphoma paper (PubMed search)](https://pubmed.ncbi.nlm.nih.gov/?term=9p24.1+amplification+JAK+inhibition+immune+checkpoint+blockade+lymphoma)** - **[Open GSE313628 in GEO (MIC13-linked cristae disruption, mitochondrial liver disease, n=16)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313628)** - **[Read MIC13 mitochondrial hepatopathy paper (PMID 42744797)](https://pubmed.ncbi.nlm.nih.gov/42744797/)** - **[Open GSE349369 in GEO (vervet monkey age-related skeletal muscle decline, transcriptome + miRNome + methylome, n=29)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE349369)** - **[Read vervet monkey multi-omic frailty paper (PubMed search)](https://pubmed.ncbi.nlm.nih.gov/?term=vervet+monkey+Chlorocebus+sabaeus+age-related+decline+skeletal+muscle+multi-omics)** - **[Open GSE351786 in GEO (inflammatory signature of fat after weight loss and regain - longevity runner-up, pdat 2026/10/22)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE351786)** - **[Request an amplifying-layer intervention-selection brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[View refractory-cancer service](https://brownbio.tech/services/refractory-cancer)** - **[View AI-DD service](https://brownbio.tech/services/ai-drug-discovery)** - **[View fibrosis service](https://brownbio.tech/services/fibrosis)** - **[View longevity service](https://brownbio.tech/services/longevity)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** - **[View comparative-biology dossier](https://brownbio.tech/services/multiomics#comparative-biology)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-10-24 06:07 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-10-24
PubMed/GEO scan · research-watcher · 06:00 KST